JUN 24, 2024 5:00 AM PDT

The Path from Traditional Monoclonal Antibodies to Next- Generation Constructs

You don't want to miss this!
To permanently access this eBook for free, fill out the short form below.
Unlock eBook

Monoclonal antibodies (mAbs) have revolutionized targeted cancer therapies with unmatched specificity and potency. Since the first mAb approval in 1986, advancements like refining hybridoma technology and the advent of phage display have significantly improved mAb efficacy and streamlined cell line development and molecule characterization. This progress has paved the way for next-generation antibody-based therapeutics. 

Antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) mark significant advances in precision medicine. BsAbs, with dual-targeting capabilities, have shown therapeutic potential beyond traditional mAbs, with nine novel bsAbs securing regulatory nods for oncology indications. ADCs such as Enhertu® combine the targeting power of mAbs with cytotoxic drugs' cell-killing force, offering "precision chemotherapy" that is projected to reach $9 billion in sales by 2028.

This ebook highlights Sartorius’ high-throughput instruments' role in developing next-generation therapies. It starts with a cross-platform analysis of anti-HER2 ADCs using live-cell analysis and high-throughput flow cytometry. The second study evaluates ADCs using 3D tumor spheroid models, providing translational insights that mimic in vivo conditions. 

A high-throughput screening process for bsAbs is presented, enhancing efficiency in identifying dual interactions within a single molecule. The discussion includes fully automated image-based screening and isolation of clones and single cells, revolutionizing industrial-scale antibody discovery workflows. The ebook concludes with insights into post-patent opportunities and biosimilars, emphasizing high-throughput screening cytometry's critical role in validation.

You May Also Like
Loading Comments...